Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026)
Quantum Biopharma (QNTM) reported Income from Continuing Operations of 2989159.0 for Q1 2026, up 12.67% on a YoY basis from 2653042.11 in Q1 2025, and down 29.92% sequentially from 2300748.0 in Q4 2025.
Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Quantum Biopharma (QNTM) has 8 years of Income from Continuing Operations data on file, last reported at 2989159.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 12.67% year-over-year to 2989159.0; the trailing twelve-month figure through Mar 2026 stood at 15030005.0 (down 14.1% YoY), and the FY2025 full-year result was 26956840.0, down 80.73% from the prior year.
- Income from Continuing Operations fell to 2989159.0 in Q1 2026, from 2300748.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5630055.0 in Q1 2022 to a low of 9847348.0 in Q1 2023.
- A 5-year average of 3167298.0 and a median of 3370402.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 274.91% in 2023 and soared 76.95% in 2024, its largest moves.
- Tracing QNTM's Income from Continuing Operations over 5 years: stood at 5630055.0 in 2022, then sank by 158.93% to 3318007.0 in 2023, then jumped by 36.91% to 2093300.0 in 2024, then fell by 9.91% to 2300748.0 in 2025, then retreated by 29.92% to 2989159.0 in 2026.
- Business Quant data shows QNTM's Income from Continuing Operations at 2989159.0 in Q1 2026, 2300748.0 in Q4 2025, and 4769697.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Quantum Biopharma | 13.00 Bn | 13.00 Bn | - | -2.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.99 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Jun 30, 2025 | -4.97 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -2.09 Mn |
| Sep 30, 2024 | -4.19 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Sep 30, 2023 | -3.32 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Jun 30, 2021 | -12.71 Mn |
| Mar 31, 2021 | 9.78 Mn |
| Sep 30, 2020 | -13.18 Mn |
| Jun 30, 2020 | -3.53 Mn |
| Mar 31, 2020 | -5.06 Mn |
| Dec 31, 2019 | -11.59 Mn |
| Sep 30, 2019 | -8.50 Mn |
| Jun 30, 2019 | -5.94 Mn |